SEC Form 4 · accession 0001415889-17-000308
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Terrence O Moore
Officer — EVP, CHIEF COMMERCIAL OFFICER
Period of report
Feb 21, 2017
Accepted (ET)
Feb 23, 2017 · 6:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 21, 2017 | M | 7,856 | $34.45 | A | 9,527 | D | |
| Common Stock | Feb 21, 2017 | S | 7,856 | $39.65 | D | 1,671 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $34.45 | Feb 21, 2017 | M | 7,856 | D | — | Mar 19, 2025 | Common Stock | 7,856 | 82,500 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016. All sales under the trading plan have been completed.
- F225% of the shares subject to the Stock Option vested and became exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.